Evidence map›Paper›PMID 41792125›Full record

ArticleNature communications2026

Targeting tRNA-dependent tyrosine usage unveils a metabolic vulnerability in hepatocellular carcinoma.

Hongli Zhang, Zixuan Wang, Yiqi Zhao, Xiya Deng, Jian Zhang, Fei Shang, Hongjie Zhang, Yan Liu, Hongbo Wang, Yating Yang and 10 more

Abstract read
In one paragraph

Article in Nature communications, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

20 authors.

Hongli Zhang *State Key Laboratory of Chemical Resource Engineering, College of Life Science and Technology, Beijing University of Chemical Technology, Beijing, P. R. China.
Zixuan Wang *State Key Laboratory of Chemical Resource Engineering, College of Life Science and Technology, Beijing University of Chemical Technology, Beijing, P. R. China.
Yiqi ZhaoState Key Laboratory of Chemical Resource Engineering, College of Life Science and Technology, Beijing University of Chemical Technology, Beijing, P. R. China.
Xiya DengState Key Laboratory of Chemical Resource Engineering, College of Life Science and Technology, Beijing University of Chemical Technology, Beijing, P. R. China.
Jian ZhangDepartment of Clinical Pathology, Nanyang Central Hospital, Nanyang, P.R. China.
Fei ShangAnalytical and Testing Centre, Beijing University of Chemical Technology, Beijing, P. R. China.
Hongjie ZhangThe Core Facilities, Institute of Biophysics, Chinese Academy of Sciences, Beijing, P. R. China.
Yan LiuThe Fifth Medical Centre of Chinese PLA General Hospital, Beijing, P.R. China.
Hongbo WangThe Fifth Medical Centre of Chinese PLA General Hospital, Beijing, P.R. China.
Yating YangState Key Laboratory of Chemical Resource Engineering, College of Life Science and Technology, Beijing University of Chemical Technology, Beijing, P. R. China.
Huiyu LinKey Laboratory of Receptors-Mediated Gene Regulation and Drug Discovery, School of Basic Medical Science, Inner Mongolia Medical University, Hohhot, P. R. China.
Bo ZhangState Key Laboratory of Chemical Resource Engineering, College of Life Science and Technology, Beijing University of Chemical Technology, Beijing, P. R. China.
Ce LiuState Key Laboratory of Chemical Resource Engineering, College of Life Science and Technology, Beijing University of Chemical Technology, Beijing, P. R. China.
Fan GuoKey Laboratory of Receptors-Mediated Gene Regulation and Drug Discovery, School of Basic Medical Science, Inner Mongolia Medical University, Hohhot, P. R. China.
Ruolin ZhangBeijing Key Laboratory of Bioprocess, College of Life Science and Technology, Beijing University of Chemical Technology, Beijing, P.R. China.
Qipeng YuanState Key Laboratory of Chemical Resource Engineering, College of Life Science and Technology, Beijing University of Chemical Technology, Beijing, P. R. China.ORCID 0000-0002-7899-1487
Yue FengState Key Laboratory of Green Biomanufacturing, College of Life Science and Technology, Beijing University of Chemical Technology, Beijing, P.R. China.ORCID 0000-0002-1576-1385
Shi-Zhong LuoBeijing Key Laboratory of Bioprocess, College of Life Science and Technology, Beijing University of Chemical Technology, Beijing, P.R. China.ORCID 0000-0002-4880-5962
Wei-Dong ChenKey Laboratory of Receptors-Mediated Gene Regulation and Drug Discovery, School of Basic Medical Science, Inner Mongolia Medical University, Hohhot, P. R. China. wdchen666@163.com.
Yan-Dong WangState Key Laboratory of Chemical Resource Engineering, College of Life Science and Technology, Beijing University of Chemical Technology, Beijing, P. R. China. ydwangbuct2009@163.com.ORCID 0000-0003-2293-5854

Funding

National Key R&D Programme of ChinaNational Natural Science Foundation of ChinNational Natural Science Foundation of China
6 · The paper itself

Abstract

Cancer cells reprogramme translation and metabolism to fuel tumorigenesis. Here, we show that hepatocellular carcinoma (HCC) paradoxically maintains low tyrosine levels despite increased uptake and reduced metabolism, redirecting tyrosine to translation via MYC-driven upregulation of tyrosyl-tRNA synthetase 1 (YARS1) and tRNA-Tyr

Indexed as

Carcinoma, HepatocellularLiver NeoplasmsRNA, Transfer, TyrTyrosineAnimalsCell Line, TumorElectron Transport Complex IFerroptosisHumansMetabolic ReprogrammingMiceOxidative PhosphorylationProtein BiosynthesisTyrosine-tRNA LigaseElectron Transport Complex IRNA, Transfer, TyrTyrosineTyrosine-tRNA Ligase

Identifiers

PMID41792125
PMCPMC12966498

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.